Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 9/20 | 0.66 |
| ▸ | LTB4R2 | Q9NPC1 | 11/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29561367 | 1.00 | AGTR1 (0.66) | AGTR1LTB4R2ABCB11GP6MME | |
| SCHEMBL2032 | 1.00 | AGTR1 (0.66) | AGTR1LTB4R2ABCB11GP6MME | |
| SCHEMBL1808771 | 1.00 | AGTR1 (0.66) | AGTR1LTB4R2ABCB11GP6MME | |
| SCHEMBL2978 | 0.93 | AGTR1 (0.57) | AGTR1LTB4R2ABCB11GP6MME | |
| SCHEMBL2979 | 0.93 | AGTR1 (0.57) | AGTR1LTB4R2ABCB11GP6MME | |
| SCHEMBL8487504 | 0.91 | AGTR1 (0.56) | AGTR1LTB4R2ABCB11GP6MME | |
| SCHEMBL2629 | 0.90 | LTB4R2 (0.54) | AGTR1LTB4R2ABCB11GP6MME | |
| SCHEMBL2628 | 0.90 | LTB4R2 (0.54) | AGTR1LTB4R2ABCB11GP6MME | |
| SCHEMBL27791229 | 0.90 | AGTR1 (0.53) | AGTR1LTB4R2ABCB11GP6MME | |
| SCHEMBL27791231 | 0.90 | AGTR1 (0.53) | AGTR1LTB4R2ABCB11GP6MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115215813-A | Method for controlling valsartan impurity | 江苏新瑞药业有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-110078640-B | Synthesis method of valsartan intermediate | 浙江美诺华药物化学有限公司 | 2022-04-05 | — | — | CN | claimed |
| EP-3939967-A1 | A CONTINUOUS PROCESS FOR THE PREPARATION OF (S)-METHYL N-((2'-CYANO-[1,1'-BIPHENYL]-4-YL)METHYL)-N-PENTANOYLVALINATE IN A FLOW REACTOR | KRKA, d.d., Novo mesto (SI) | 2022-01-19 | — | — | EP | claimed |
| US-7659406-B2 | Process for preparing valsartan | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-02-09 | — | — | US | claimed |
| US-20060149079-A1 | Process for preparing valsartan | DR. REDDY'S LABORATORIES, INC. | 2006-07-06 | — | — | US | claimed |
| EP-4037679-B1 | A PROCESS FOR THE PREPARATION OF HIGHLY PURE VALSARTAN | HARMAN FINOCHEM LTD (IN) | 2025-08-06 | — | — | EP | disclosed |
| US-12365654-B2 | Process for the preparation of highly pure valsartan | HARMAN FINOCHEM LIMITED (IN) | 2025-07-22 | — | — | US | disclosed |
| WO-2023148748-A1 | AN IMPROVED SAFE PROCESS FOR THE PREPARATION OF SARTAN DRUGS OF FORMULA I | IOL CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023148748-A1 | AN IMPROVED SAFE PROCESS FOR THE PREPARATION OF SARTAN DRUGS OF FORMULA I | IOL CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |
| US-11655220-B2 | Process for the preparation of angiotensin II receptor blockers | HETERO LABS LIMITED (IN) | 2023-05-23 | — | — | US | disclosed |
| US-20230057675-A1 | A PROCESS FOR THE PREPARATION OF HIGHLY PURE VALSARTAN | HARMAN FINOCHEM LIMITED (IN) | 2023-02-23 | — | — | US | disclosed |
| US-20230057675-A1 | A PROCESS FOR THE PREPARATION OF HIGHLY PURE VALSARTAN | HARMAN FINOCHEM LIMITED (IN) | 2023-02-23 | — | — | US | disclosed |
| WO-2005049587-A1 | PROCESS FOR PREPARATION OF BIPHENYL TETRAZOLE | RANBAXY LABORATORIES LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
| WO-2004111018-A1 | A NOVEL PROCESS FOR PREPARATION OF VALSARTAN | HETERO DRUGS LIMITED (IN) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004101534-A1 | A METHOD OF PREPARATION OF N-(1-OXOPENTYL)-N-[[2'-(1H-TETRAZOL-5-y1) [1,1'-BIPHENYL] -4-y1]METHYL]-L-VALINE (VALSARTAN) | ZENTIVA, A. S. (CZ) | 2004-11-25 | — | — | WO | disclosed |
| US-20040072886-A1 | Novel crystalline forms of (S)-N- (1-Carboxy-2-methyl-prop-1-yl) -N-pentanoyl-N- [2' -(1H-tetrazol-5-yl)- biphenyl-4-yl methyl] amine (Valsartan) | DR. REDDY'S LABORATORIES LIMITED | 2004-04-15 | — | — | US | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057675-A1 | A PROCESS FOR THE PREPARATION OF HIGHLY PURE VALSARTAN | REN, AGT, ACE | AGTR1 4/4885LTB4R2 2553/4885ABCB11 1169/4885 |
| US-12365654-B2 | Process for the preparation of highly pure valsartan | REN, AGT, ACE | AGTR1 4/4885LTB4R2 2074/4885ABCB11 1142/4885 |
| US-20040072886-A1 | Novel crystalline forms of (S)-N- (1-Carboxy-2-methyl-prop-1-yl) -N-pentanoyl-N- [2' -(1H-tetrazol-5-yl)- biphenyl-4-yl methyl] amine (Valsartan) | REN, AGTR1, TTR | AGTR1 2/4885LTB4R2 2812/4885ABCB11 3133/4885 |
| US-11655220-B2 | Process for the preparation of angiotensin II receptor blockers | AGTR2, AGTR1, ADRB1 | AGTR1 2/4885LTB4R2 725/4885ABCB11 2292/4885 |
| US-20060149079-A1 | Process for preparing valsartan | PREP, TMPRSS15, REN | AGTR1 14/4885LTB4R2 2490/4885ABCB11 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.